Method and system for automated image analysis in cancer cells

• US 9,080,203 B2
• Filed: 09/03/2014
• Issued: 07/14/2015
• Est. Priority Date: 07/21/2009
• Status: Active Grant

• Current Assignee: NeoDiagnostix, Inc. (Bristol-Myers Squibb Company)
• Original Assignee: NeoDiagnostix, Inc. (Bristol-Myers Squibb Company)
• Inventors: Endress, Gregory Anton, Upender, Madhvi, Light, Elizabeth, Cain, Colyn
• Primary Examiner(s): Joike, Michele K
• Assistant Examiner(s): Brown, Mindy G
• Application Number:
  US14/475,617
• Publication Number:
  US 20150024395A1
• Time in Patent Office: 314 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: C12Q 1/6816 characterised by the detection means C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6841 In situ hybridisation
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2565/601 being a microscope, e.g. atomic force microscopy [AFM]
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G06T 2207/10024 Color image
• CPC Class Codes: G06T 2207/10056 Microscopic image
• CPC Class Codes: G06T 2207/10064 Fluorescence image
• CPC Class Codes: G06T 2207/30024 Cell structures in vitro; Tissue sections in vitro
• CPC Class Codes: G06T 7/0012 Biomedical image inspection
• CPC Class Codes: G06V 20/698 Matching; Classification

Abstract

A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.

Claims

1. An automated method for detecting chromosomal abnormalities in a plurality of cells in a cervical sample, said method comprising:

a) hybridizing nucleic acid probes to a target, wherein the target comprises EVII or MDS1;

b) detecting the hybridization signal of the nucleic acid probes, wherein the hybridization signal is indicative of chromosomal copy number for the target;

c) scoring the chromosomal copy number of the target ; and

d) reporting whether the sample contains chromosomal abnormalities wherein the sample is determined to be negative or have normal ploidy when a gain of chromosomal copy number is in less than 0.9% of the cells.

2. The method of claim 1, wherein the scoring of the chromosomal copy number is performed by counting the cells having chromosomal abnormalities.

3. The method of claim 1, wherein the scoring of the chromosomal copy number is performed by counting hybridization signals.

4. The method according to claim 1, wherein the method is performed by using an automated microscope.

5. The method according to claim 1, wherein the cells in said sample are deposited in a thin layer on a slide.

6. The method of claim 1, wherein the hybridization is detected by FISH, CISH, PCR, ELISA, CGH, Array CGH or flow cytometry.

7. The method of claim 1, wherein the target further comprises TERC, APRM1, or MYNN.

8. The method of claim 7, wherein the target further comprises a locus at 5p15, 5p15.3, or 5p15.2.

9. The method of claim 7, wherein the target further comprises TERT, TRIP13, or Cri du Chat locus at 5p15.2.

10. The method of claim 7, wherein the target further comprises CEN7 or CEN3.

11. The method of claim 7, wherein the target further comprises a locus at chromosome 1q or 20q.

12. The method of claim 7, wherein at least 800 cells are examined.

13. The method of claim 7, wherein at least 1000 cells are examined.

14. The method of claim 7, wherein the target comprises TERC, APRM1, and MYNN.

15. The method of claim 7, wherein the target further comprises LRRC34.

16. The method of claim 15, wherein the target further comprises a locus at 5p15, 5p15.3, or 5p15.2.

17. The method of claim 15, wherein the target further comprises TERT, TRIP13, or Cri du Chat locus at 5p15.2.

18. The method of claim 15, wherein the target further comprises CEN7 or CEN3.

19. The method of claim 15, wherein the target further comprises a locus at chromosome 1q or 20q.

20. The method of claim 15, wherein at least 800 cells are examined.

21. The method of claim 15, wherein at least 1000 cells are examined.

22. The method of claim 15, wherein the target further comprises SAMD7, LOC1000128164, SEC62, GPR160, PHC3, GPR160, PHC3 or PRKCI.

23. The method of claim 22, wherein the target further comprises a locus at 5p15, 5p15.3, or 5p15.2.

24. The method of claim 22, wherein the target further comprises TERT, TRIP13, or Cri du Chat locus at 5p15.2.

25. The method of claim 22, wherein the target further comprises CEN7 or CEN3.

26. The method of claim 22, wherein the target further comprises a locus at chromosome 1q or 20q.

27. The method of claim 22, wherein at least 800 cells are examined.

28. The method of claim 22, wherein at least 1000 cells are examined.

29. The method of claim 22, wherein the target comprises SAMD7, LOC1000128164, SEC62, GPR160, and PHC3.

30. The method of claim 22, wherein the target comprises GPR160, PHC3, and PRKCI.

31. The method of claim 7, wherein at least 50 cells are examined.

32. The method of claim 15, wherein at least 50 cells are examined.

33. The method of claim 22, wherein at least 50 cells are examined.